NCT05539027View on ClinicalTrials.gov

Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients With Hepatic Encephalopathy

PHASE4CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

September 20, 2022

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions
Hepatic Encephalopathy
Interventions
DRUG

Branched-chain amino acids (BCAA), enriched solution (Aminoleban) and L-ornithine L-aspartate (LOLA)

patients will receive branched-chain amino acids (BCAA), enriched solution (Aminoleban) and L-ornithine L-aspartate (LOLA)

DRUG

Branched-chain amino acids (BCAA), enriched solution (Aminoleban)

patients will receive BCAA enriched solution (Aminoleban)

Trial Locations (1)

11361

Ain-Shams University Hospitals, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER